Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 17
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mitochondrial DNA Haplogroup JT is Related to Impaired Glycaemic Control and Renal Function in Type 2 Diabetic Patients

  • Diaz-Morales, N.
  • Lopez-Domenech, S.
  • Iannantuoni, F.
  • Lopez-Gallardo, E.
  • Sola, E.
  • Morillas, C.
  • Rocha, M.
  • Ruiz-Pesini, E.
  • Victor, V.M.
The association between mitochondrial DNA (mtDNA) haplogroup and risk of type 2 diabetes (T2D) is undetermined and controversial. This study aims to evaluate the impact of the main mtDNA haplogroups on glycaemic control and renal function in a Spanish population of 303 T2D patients and 153 healthy controls. Anthropometrical and metabolic parameters were assessed and mtDNA haplogroup was determined in each individual. Distribution of the different haplogroups was similar in diabetic and healthy populations and, as expected, T2D patients showed poorer glycaemic control and renal function than controls. T2D patients belonging to the JT haplogroup (polymorphism m.4216T>C) displayed statistically significant higher levels of fasting glucose and HbA(1c) than those of the other haplogroups, suggesting a poorer glycaemic control. Furthermore, diabetic patients with the JT haplogroup showed a worse kidney function than those with other haplogroups, evident by higher levels of serum creatinine, lower estimated glomerular filtration rate (eGFR), and slightly higher (although not statistically significant) urinary albumin-to-creatinine ratio. Our results suggest that JT haplogroup (in particular, change at position 4216 of the mtDNA) is associated with poorer glycaemic control in T2D, which can trigger the development of diabetic nephropathy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Las enfermedades raras en las patologías neurometabólicas

  • Montoya, J.
  • Arenas, J.
  • Ruiz-Pesini, E.
  • Martin-Casanueva, M.A.
Las miopatías metabólicas son un grupo de trastornos genéticos que disminuyen la capacidad del músculo esquelético para utilizar sustratos energéticos y sintetizar ATP. Estas alteraciones pueden clasificarse en tres tipos fundamentalmente: i) trastornos del metabolismo de los carbohidratos (del glucógeno y de la glucosa), ii) defectos del metabolismo lipídico, y iii) alteraciones de la fosforilación oxidativa –OXPHOS-. Las dos primeras se deben a deficiencias enzimáticas de las rutas metabólicas de degradación y síntesis de glúcidos y lípidos y muestran diversas manifestaciones clínicas, pero una buena parte de ellas cursan con intolerancia al ejercicio. Aunque un buen número de pacientes con estos trastornos musculares presentan síntomas en la infancia, el diagnóstico normalmente se retrasa hasta la segunda y tercera década de la vida. Por tanto, reconocer las características clínicas de estas deficiencias conduce a un diagnóstico precoz y a un mejor tratamiento. Las enfermedades mitocondriales son un grupo de trastornos originados por una deficiencia en la síntesis de ATP a través del sistema de fosforilación oxidativa. Este sistema está formado por proteínas codificadas en los dos genomas de la célula (nuclear y mitocondrial) y, por tanto, pueden presentar un modelo de herencia mendeliano o materno. En esta revisión se describirán las características especiales del sistema genético mitocondrial y las principales mutaciones que causan enfermedades en humanos. Metabolic myopathies are genetic disorders that decrease the capacity of skeletal muscle to use energy substrates and ATP. These disturbances can be classified into three categories: i) disorders of carbohydrate metabolism (glycogen and glucose), ii) defects in lipid metabolism, and iii) dysfunctions of oxidative phosphorylation -OXPHOS-. The first two are caused by enzyme deficiencies involved in the metabolic pathways of degradation and synthesis of carbohydrates and lipids, and although they show distinct clinical manifestations, exercise intolerance is a predominant symptom present in most of them. Although a good number of patients with these muscle disorders display symptoms in childhood, the diagnosis is often delayed until the second and third decades of life. Therefore, recognizing the clinical features of these deficiencies can lead to an earlier diagnosis and better treatment. Mitochondrial diseases are a group of disorders caused by an alteration of the oxidative phosphorylation system, that leads to a deficient synthesis of ATP. This system is composed of proteins codified in the two genetic systems of the cell, the nuclear and mitochondrial genomes, and, therefore, the mode of inheritance could be either Mendelian or maternal. This review will describe the special characteristics of the mitochondrial genetic system and the main mutations in mtDNA that cause human diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Increasing mtDNA levels as therapy for mitochondrial optic neuropathies

  • Ruiz-Pesini, E.
  • Emperador, S.
  • López-Gallardo, E.
  • Hernández-Ainsa, C.
  • Montoya, J.
Leber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Food derived respiratory complex I inhibitors modify the effect of Leber hereditary optic neuropathy mutations

  • López-Gallardo, E.
  • Emperador, S.
  • Hernández-Ainsa, C.
  • Montoya, J.
  • Bayona-Bafaluy, M.P.
  • Ruiz-Pesini, E.
Mitochondrial DNA mutations in genes encoding respiratory complex I polypeptides can cause Leber hereditary optic neuropathy. Toxics affecting oxidative phosphorylation system can also cause mitochondrial optic neuropathy. Some complex I inhibitors found in edible plants might differentially interact with these pathologic mutations and modify their penetrance. To analyze this interaction, we have compared the effect of rotenone, capsaicin and rolliniastatin-1 on cybrids harboring the most frequent Leber hereditary optic neuropathy mutations and found that m.3460G > A mutation increases rotenone resistance but capsaicin and rolliniastatin-1 susceptibility. Thus, to explain the pathogenicity of mitochondrial diseases due to mitochondrial DNA mutations, their potential interactions with environment factors will have to be considered.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutations of the mitochondrial carrier translocase channel subunit TIM22 cause early-onset mitochondrial myopathy

  • Pacheu-Grau, David
  • Callegari, Sylvie
  • Emperador, Sonia
  • Thompson, Kyle
  • Aich, Abhishek
  • Topol, Sarah E.
  • Spencer, Emily G.
  • McFarland, Robert
  • Ruiz-Pesini, Eduardo
  • Torkamani, Ali
  • Taylor, Robert W.
  • Montoya, Julo
  • Rehling, Peter
Protein import into mitochondria is facilitated by translocases within the outer and the inner mitochondrial membranes that are dedicated to a highly specific subset of client proteins. The mitochondrial carrier translocase (TIM22 complex) inserts multispanning proteins, such as mitochondrial metabolite carriers and translocase subunits (TIM23, TIM17A/B and TIM22), into the inner mitochondrial membrane. Both types of substrates are essential for mitochondrial metabolic function and biogenesis. Here, we report on a subject, diagnosed at 1.5 years, with a neuromuscular presentation, comprising hypotonia, gastroesophageal reflux disease and persistently elevated serum and Cerebrospinal fluid lactate (CSF). Patient fibroblasts displayed reduced oxidative capacity and altered mitochondrial morphology. Using trans-mitochondrial cybrid cell lines, we excluded a candidate variant in mitochondrial DNA as causative of these effects. Whole-exome sequencing identified compound heterozygous variants in the TIM22 gene (NM_013337), resulting in premature truncation in one allele (p.Tyr25Ter) and a point mutation in a conserved residue (p.Val33Leu), within the intermembrane space region, of the TIM22 protein in the second allele. Although mRNA transcripts of TIM22 were elevated, biochemical analyses revealed lower levels of TIM22 protein and an even greater deficiency of TIM22 complex formation. In agreement with a defect in carrier translocase function, carrier protein amounts in the inner membrane were found to be reduced. This is the first report of pathogenic variants in the TIM22 pore-forming subunit of the carrier translocase affecting the biogenesis of inner mitochondrial membrane proteins critical for metabolite exchange.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: Identification of deletions and variants

  • Saldaña-Martínez, A.
  • Muñoz, M.D.L.
  • Pérez-Ramírez, G.
  • Montiel-Sosa, J.F.
  • Montoya, J.
  • Emperador, S.
  • Ruiz-Pesini, E.
  • Cuevas-Covarrubias, S.
  • López-Valdez, J.
  • Ramírez, R.G.
Mitochondria both produce the energy of the cell as ATP via respiration and regulate cellular metabolism. Accordingly, any deletion or mutation in the mitochondrial DNA (mtDNA) may result in a disease. One of these diseases is Kearns Sayre syndrome (KSS), described for the first time in 1958, where different large-scale deletions of different sizes and at different positions have been reported in the mitochondrial genome of patients with similar clinical symptoms. In this study, sequences of the mitochondrial genome of three patients with clinic features of KSS were analyzed. Our results revealed the position, heteroplasmy percentage, size of deletions, and their haplogroups. Two patients contained deletions reported previously and one patient showed a new deletion not reported previously. These results display for the first time a systematic analysis of mtDNA variants in the whole mtDNA genome of patients with KSS to help to understand their association with the disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Molecular characterization of new FBXL4 mutations in patients with mtDNA depletion syndrome

  • Emperador, Sonia
  • Garrido-Pérez, Nuria
  • Amezcua-Gil, Javier
  • Gaudó, Paula
  • Andrés-Sanz, Julio Alberto
  • Yubero, Delia
  • Fernández-Marmiesse, Ana
  • O'Callaghan, Maria M
  • Ortigoza-Escobar, Juan D.
  • Iriondo, Marti
  • Ruiz-Pesini, Eduardo
  • García-Cazorla, Angels
  • Gil-Campos, Mercedes
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Oxidative phosphorylation inducers fight pathological angiogenesis

  • Bayona-Bafaluy, M.P.
  • Esteban, O.
  • Ascaso, J.
  • Montoya, J.
  • Ruiz-Pesini, E.
Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases, or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising therapeutic approach for pathologic angiogenesis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Oxidative phosphorylation dysfunction modifies the cell secretome

  • Garrido-Pérez, Nuria
  • Vela-Sebastián, Ana
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Iglesias, Eldris
  • Meade, Patricia
  • Jiménez-Mallebrera, Cecilia
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell’s secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation.

  • Emperador, Sonia
  • López-Gallardo, Ester
  • Hernández-Ainsa, Carmen
  • Habbane, Mouna
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Background: The vision loss in Leber hereditary optic neuropathy patients is due to mitochondrial DNA mutations. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. However, clinical evidences suggest two therapeutic approaches: the reduction of the mutation load in heteroplasmic patients or the elevation of mitochondrial DNA amount in homoplasmic patients. Results: Here we show that ketogenic treatment, in cybrid cell lines, reduces the percentage of the m.13094 T > C heteroplasmic mutation and also increases the mitochondrial DNA levels of the m.11778G > A mitochondrial genotype. Conclusions: These results suggest that ketogenic diet could be a therapeutic strategy for Leber hereditary optic neuropathy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Brain pyrimidine nucleotide synthesis and Alzheimer disease

  • Pesini, Alba
  • Iglesias, Eldris
  • Bayona-Bafaluy, M Pilar
  • Garrido-Pérez, Nuria
  • Meade, Patricia
  • Gaudó, Paula
  • Jiménez-Salvador, Irene
  • Andrés-Benito, Pol
  • Montoya, Julio
  • Ferrer, Isidro
  • Pesini, Pedro
  • Ruiz-Pesini, Eduardo
Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Oxidative phosphorylation system and cell culture media

  • Bayona-Bafaluy, M.P.
  • Montoya, J.
  • Ruiz-Pesini, E.
Traditional culture media do not re-semble the metabolic compositionof human blood. The concentrationof different metabolites in thesemedia influences mitochondrialbiogenesis and oxidative phos-phorylation (OXPHOS) function.This knowledge is essential for theinterpretation of results obtainedfrom cellular models used for thestudy of OXPHOS function.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Síndrome de Leigh de inicio adulto, con epilepsia mioclónica progresiva, asociado a la mutación m.14487T>C: reporte de caso

  • Segura-Chávez, Darwin
  • Torres-Ramírez, Luis
  • Emperador-Ortiz, Sonia
  • Vélez-Rojas, Miriam
  • Flores-Mendoza, Martha
  • Cosentino-Esquerre, Carlos
  • Ruiz-Pesini, Eduardo
  • Montoya-Villarroya, Julio
El síndrome de Leigh o encefalomielopatía necrotizante subaguda es una enfermedad neurodegenerativa progresiva, genética y clínicamente heterogénea que se asocia por lo general con alteración del metabolismo mitocondrial a nivel de la fosforilación oxidativa. Se presenta generalmente en el periodo neonatal, pero también en la edad adulta, en la que suele expresarse con una combinación de diversas manifestaciones entre ellas parkinsonismo, alteraciones del movimiento, alteraciones neuropsiquiátricas y otras. Caso clínico Paciente masculino de 34 años de edad, que inició sus síntomas a los 18 años, algunos meses después de que su madre falleciera con síntomas parecidos, pero sin diagnóstico definido. El paciente presentó mioclonías progresivas en miembro superior derecho, espasmos palpebrales bilaterales y cervicales, asociándose posteriormente, mioclonia facial desencadenado por el habla y distonía en miembro inferior derecho que le impedía la deambulación. La resonancia magnética de encéfalo mostró la presencia de lesiones simétricas bilaterales en núcleos basales, lesiones corticales y periacueductales. El estudio genético detectó la mutación m.14487T>C en el gen ND6 del complejo 1 del sistema de fosforilación oxidativa mitocondrial en los leucocitos y células de mucosa bucal. El estudio se extendió a la abuela y dos tías maternas, asintomáticas en ese momento, quienes portaban la misma mutación. Conclusión El caso corresponde a un paciente adulto, con síndrome de Leigh, portador de la mutación m.14487T>C, la cual parece estar relacionada con un fenotipo predominantemente mioclónico progresivo, de origen cortical.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Prenatal exposure to oxidative phosphorylation xenobiotics and late-onset Parkinson disease

  • Iglesias, E.
  • Pesini, A.
  • Garrido-Pérez, N.
  • Meade, P.
  • Bayona-Bafaluy, M.P.
  • Montoya, J.
  • Ruiz-Pesini, E.
Late-onset Parkinson disease is a multifactorial and multietiological disorder, age being one of the factors implicated. Genetic and/or environmental factors, such as pesticides, can also be involved. Up to 80% of dopaminergic neurons of the substantia nigra are lost before motor features of the disorder begin to appear. In humans, these neurons are only formed a few weeks after fertilization. Therefore, prenatal exposure to pesticides or industrial chemicals during crucial steps of brain development might also alter their proliferation and differentiation. Oxidative phosphorylation is one of the metabolic pathways sensitive to environmental toxicants and it is crucial for neuronal differentiation. Many inhibitors of this biochemical pathway, frequently found as persistent organic pollutants, affect dopaminergic neurogenesis, promote the degeneration of these neurons and increase the risk of suffering late-onset Parkinson disease. Here, we discuss how an early, prenatal, exposure to these oxidative phosphorylation xenobiotics might trigger a late-onset, old age, Parkinson disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Down syndrome is an oxidative phosphorylation disorder

  • Bayona-Bafaluy, M.P.
  • Garrido-Pérez, N.
  • Meade, P.
  • Iglesias, E.
  • Jiménez-Salvador, I.
  • Montoya, J.
  • Martínez-Cué, C.
  • Ruiz-Pesini, E.
Down syndrome is the most common genomic disorder of intellectual disability and is caused by trisomy of chromosome 21. Several genes in this chromosome repress mitochondrial biogenesis. The goal of this study was to evaluate whether early overexpression of these genes may cause a prenatal impairment of oxidative phosphorylation negatively affecting neurogenesis. Reduction in the mitochondrial energy production and a lower mitochondrial function have been reported in diverse tissues or cell types, and also at any age, including early fetuses, suggesting that a defect in oxidative phosphorylation is an early and general event in Down syndrome individuals. Moreover, many of the medical conditions associated with Down syndrome are also frequently found in patients with oxidative phosphorylation disease. Several drugs that enhance mitochondrial biogenesis are nowadays available and some of them have been already tested in mouse models of Down syndrome restoring neurogenesis and cognitive defects. Because neurogenesis relies on a correct mitochondrial function and critical periods of brain development occur mainly in the prenatal and early neonatal stages, therapeutic approaches intended to improve oxidative phosphorylation should be provided in these periods.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Infectious stress triggers a POLG-related mitochondrial disease

  • Gaudo, Paula
  • Emperador, Sonia
  • Garrido-Perez, Nuria
  • Ruiz-Pesini, Eduardo
  • Yubero, Delia
  • Garcia-Cazorla, Angels
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
A 3-year-old girl presented with severe epilepsy in the context of Borrelia infection. After ceftriaxone/lidocaine administration, she showed secondarily generalized focal crises that led to neurological and motor sequelae. Genetic studies identified in the patient two heterozygous POLG mutations (c.2591A>G; p.Asn864Ser and c.3649G>C; p.Ala1217Pro). Through analysis of POLG activity in cultured fibroblasts, we confirmed that the mutations altered the mtDNA turnover. Moreover, patient fibroblasts were more sensitive than controls in the presence of a mitochondrial replication-affecting drug, the antiretroviral azidothymidine. To test if ceftriaxone treatment could worsen the deleterious effect of the patient mutations, toxicity assays were performed. Cell toxicity, without direct effect on mitochondrial respiratory function, was detected at different antibiotic concentrations. The clinical outcome, together with the different in vitro sensitivity to ceftriaxone among patient and control cells, suggested that the mitochondrial disease symptoms were hastened by the infection and were possibly worsened by the pharmacological treatment. This study underscores the benefit of early genetic diagnosis of the patients with mitochondrial diseases, since they may be a target group of patients especially vulnerable to environmental factors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pathological Features in Paediatric Patients with TK2 Deficiency

  • Jou, Cristina|||0000-0002-2223-7880
  • Nascimento, Andres
  • Codina, Anna
  • Montoya, Julio|||0000-0003-1770-6299
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Montero, Raquel|||0000-0003-0609-5701
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Marquez, Jesus
  • Zelaya, Maria Victoria|||0000-0002-3692-3515
  • Gutierrez-Mata, Alfonso
  • Badosa, Carmen
  • Carrera-García, Laura|||0000-0003-4762-7591
  • Expósito-Escudero, Jesica|||0000-0002-6233-823X
  • Roldan Molina, Mònica|||0000-0002-9530-6234
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Artuch, R.|||0000-0002-3422-9685
Thymidine kinase (TK2) deficiency causes mitochondrial DNA depletion syndrome. We aimed to report the clinical, biochemical, genetic, histopathological, and ultrastructural features of a cohort of paediatric patients with TK2 deficiency. Mitochondrial DNA was isolated from muscle biopsies to assess depletions and deletions. The TK2 genes were sequenced using Sanger sequencing from genomic DNA. All muscle biopsies presented ragged red fibres (RRFs), and the prevalence was greater in younger ages, along with an increase in succinate dehydrogenase (SDH) activity and cytochrome c oxidase (COX)-negative fibres. An endomysial inflammatory infiltrate was observed in younger patients and was accompanied by an overexpression of major histocompatibility complex type I (MHC I). The immunofluorescence study for complex I and IV showed a greater number of fibres than those that were visualized by COX staining. In the ultrastructural analysis, we found three major types of mitochondrial alterations, consisting of concentrically arranged lamellar cristae, electrodense granules, and intramitochondrial vacuoles. The pathological features in the muscle showed substantial differences in the youngest patients when compared with those that had a later onset of the disease. Additional ultrastructural features are described in the muscle biopsy, such as sarcomeric de-structuration in the youngest patients with a more severe phenotype.